Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes - Slideshow

{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895295-biomea-fusion-inc-bmea-discusses-top-line-results-from-covalentminus-112-trial-of-icovamenib"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.